The disappointment of Galapagos in the study of possible arthrosis drug

Galapagos has encountered a disappointment when investigating a potential cure for osteoarthritis. The study did not provide statistically significant evidence that the candidate drug GLPG1972 counteracts knee cartilage loss in patients with osteoarthritis.

The main purpose of the Phase 2 study was precisely to demonstrate that GLPG1972 has an effect on cartilage development. Osteoarthritis is a joint disease caused by loss of cartilage.

The research was carried out in collaboration with the French pharmaceutical company Servier. The latter company has a license deal with Galapagos for the sale of the potential arthrosis drug outside the United States. Galapagos and Servier have been working together for a long time on the candidate drug against joint wear, which is not yet a medicine against.